Actively Recruiting
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor
Led by University Hospital, Basel, Switzerland · Updated on 2024-12-11
120
Participants Needed
1
Research Sites
343 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.
CONDITIONS
Official Title
Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age �3E�3D 18 years
- Admission to intensive care unit
- Need for platelet transfusion during or after surgery with or without prior treatment with single or dual antiplatelet agents (ASS, Prasugrel, Clopidogrel, Ticagrelor)
- Consent by the patient or a family member in addition to the consent of an independent ICU physician
You will not qualify if you...
- Receiving Factor VIII concentrate before study inclusion (Haemate �AE)
- Women who are pregnant or breastfeeding
- Participation in another investigational drug study within 30 days before or during this study
- Overt Disseminated Intravascular Coagulation (DIC)
- Heparin-induced Thrombocytopenia (HIT)
- Thrombotic Thrombocytopenic Purpura (TTP) or Haemolytic Uremic Syndrome (HUS)
- Idiopathic thrombocytopenic purpura (ITP)
- Sepsis
- Known inherited thrombocytopathies
- Known von Willebrand disease or Haemophilia A
- Known hemato-oncological diseases
- Previous enrollment in this study
- Contraindications to the study drug class, such as known hypersensitivity or allergy to the investigational product
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
M
Martin Siegemund, Prof. Dr. MD
CONTACT
A
Andrea Blum, med. pract.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here